Malaria Vaccine: AdFalciVax

In September 2025, the Indian Council of Medical Research (ICMR) granted non-exclusive rights for its multi-stage malaria vaccine, AdFalciVax, to five pharmaceutical companies.

  • AdFalciVax is India’s first indigenous multi-stage malaria recombinant vaccine developed by the Regional Medical Research Centre (RMRC), Bhubaneswar, under the ICMR.
  • The primary objective of this vaccine is to prevent infection caused by Plasmodium falciparum and to reduce malaria transmission at the community level.

Specifications of AdFalciVax

  • AdFalciVax targets the parasite before it enters the bloodstream, stopping the infection at the transmission stage
  • The vaccine uses Lactococcus lactis, a genetically engineered food-grade bacterial host, as its core technology
  • It delivers a ....
Do You Want to Read More?
Subscribe Now
To get access to detailed content
Buy May 2026 Issue

Already a Member? Login here

Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material before the last six months of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.
Be an Annual Subscriber

Related Content

Current Affairs